Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to improve the lives of people with cancer. Using its proprietary switch-control kinase inhibitor platform and capabilities in kinase biology, Co. designs kinase inhibitors to target the switch pocket region of the kinase with the goal of developing medicines. QINLOCK, Co.'s switch-control kinase inhibitor, was developed using Co.'s proprietary drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor. Co. has developed a pipeline of drug candidates, including vimseltinib and DCC-3116.